Unlock instant, AI-driven research and patent intelligence for your innovation.

Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor

一种肝细胞生长因子、侧索硬化症的技术,应用在利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物领域,能够解决无肌萎缩性侧索硬化症预防或治疗剂等问题

Active Publication Date: 2016-06-15
HELIXMITH CO LTD
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Nevertheless, at present, there is no effective prophylactic or therapeutic agent for ALS other than riluzole, whose clinical usefulness is ambiguous as described above, and thus there is currently a need to develop a drug for ALS. Drugs that may exhibit prophylactic or therapeutic effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
  • Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
  • Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0091] Example 1: Confirmation of the efficacy of pCK-hepatocyte growth factor X7 production in the maturation of embryonic neuronal cells (ENC)

[0092] Only the cerebral cortex was harvested from mouse embryos (embryo) and monocellularized, and 10 μM of cytarabine (Ara-C) was added to the culture medium to culture only neurons. To confirm the effect of pCK-HGFX7 production on the maturation of embryonic neurons, seed 2×10 4 cells, and the next day, the cells were treated with 1.25 ng / mL protein obtained from 293F cells transfected with pCK-HGF X7 (Lifetechnologies, USA) to confirm The degree of neurite outgrowth exhibited in the maturation of the cells. Regarding the degree of neurite outgrowth of cells, expression of TUJ-1, which is a neuron-specific tubulin, was confirmed by immunocytochemistry.

[0093] As a result, such as figure 1 As shown, it was confirmed that the pCK-hepatocyte growth factor X7-treated group more significantly increased the length of neurite compa...

Embodiment 2

[0094] Example 2: Confirmation of the effect of pCK-hepatocyte growth factor X7 on cell growth after maturation of embryonic nerve cells

[0095] The effect of pCK-hepatocyte growth factor X7 on cell growth after maturation of embryonic neural cells was confirmed. For this, seed 5×10 4 embryonic neurons and undergo a 6-day maturation process. Six days later, the protein obtained from 293F cells transfected with pCK-hepatocyte growth factor X7 was treated with 1.25 ng / mL to confirm the effect of pCK-hepatocyte growth factor X7 on the growth of the cells. After 3 days of pCK-hepatocyte growth factor X7 treatment, MTT assay was performed to measure cell growth.

[0096] As a result, such as figure 2 As shown, it was confirmed that cell growth increased by about 40% in the pCK-hepatocyte growth factor X7-treated group compared with the pCK-treated group as the control group.

Embodiment 3

[0097] Example 3: Confirmation of the effect of pCK-hepatocyte growth factor X7 on cell growth and apoptosis in mouse motor neuron cells (NSC-34)

[0098] 3-1. Cell lines and cell culture

[0099] The mouse motor nerve cells (Cellution Biosystem, Vancouver, CA) used in this experiment are motor nerve cells derived from mice. Mouse motor nerve cells are a cell line that is a mixture of motor nerve cells and neuroblastoma cells derived from mouse spinal nerves during the embryonic period, and is widely used in studies related to motor nerves. Incubate the above cells at 37°C and 5% CO 2 Cultivate under conditions, and culture in Dulbecco's modified Eagle including 10% bovine fetal serum (Gibco, USA) and antibiotics (Gibco, BRL, USA) culture medium (DMEM, Sigma). Cell culture media, reagents and sera were purchased from Gebico and Sigmaaldrich.

[0100] 3-2. Production and quantification of supernatant expressing hepatocyte growth factor protein

[0101] To produce supernata...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide encoding the isoforms. The composition of the present invention is used to effectively prevent or treat amyotrophic lateral sclerosis.

Description

technical field [0001] This patent application claims priority over Korean Patent Application No. KR10-2013-0126216 filed with the Korean Patent Office on October 22, 2013 and Korean Patent Application No. KR10-2014-0143377 filed with the Korean Patent Office on October 22, 2014 , the disclosures of the above patent applications are incorporated herein by reference. [0002] The present invention relates to a composition for the prevention or treatment of amyotrophic lateral sclerosis, comprising two or more isomers of hepatocyte growth factor or polynucleotides encoding the isomers as active ingredients. Background technique [0003] Amyotrophic lateral sclerosis (Amyotrophic Lateral Sclerosis: ALS), as a disease occurring in motor neurons, was first reported by French doctor Jean-Martin Chartcot in 1869. Later, in 1939, Lou Gehrig, a famous baseball player in the United States, suffered from this disease, and it became known to the general public, and it has since been ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61P21/00
CPCC07K14/4753A61K38/1833A61P21/00A61P21/02A61P25/28A61K38/18A61K31/7088C12Q1/686
Inventor 郑在均
Owner HELIXMITH CO LTD